Freight Technologies, Inc. (FRGT) +28.37%
Fr8App Awarded Key Routes with Envases Universales
In a major development, Freight Technologies, Inc. (FRGT) has announced a strategic collaboration with Envases Universales, a global packaging giant. Fr8App, a subsidiary of FRGT, secured key routes through Envases’ 2024 RFQ, signifying its commitment to delivering exceptional transportation services. The deal, valued at over $5 million for the next twelve months, includes 24 dedicated lanes, primarily from Mexico to the United States, showcasing Fr8App’s robust network and cross-border logistics proficiency.
Javier Selgas, CEO of Fr8App, expressed enthusiasm, stating, “We are thrilled to have been chosen by Envases Universales to help manage their transportation needs over the coming year. This collaboration not only speaks to our capabilities but also to the trust Envases Universales has in our ability to deliver exceptional service.”
This strategic partnership emphasizes the importance of collaborative efforts in achieving excellence in logistics execution and driving profitable growth. With Fr8App’s advanced technology and experienced team, the company is poised to efficiently transport over 1,600 loads, ensuring the timely and secure delivery of Envases Universales’ goods.
ImmunityBio, Inc. (IBRX) +13.43%
Advancements in Cancer Vaccine Trial
ImmunityBio, Inc. (IBRX) has reached a significant milestone in its clinical trial focused on cancer prevention. The safety portions of the trial, studying a tri-valent combination of antigens delivered by a second-generation Adenovirus vector (Tri-Ad5 CEA/MUC1/brachyury) along with IL-15 superagonist N-803, have been fully accrued. The trial, sponsored by the National Cancer Institute, is now advancing to the randomized controlled phase.
The Tri-Ad5 vaccine targets proteins associated with precancer and cancer cells, aiming to activate dendritic cells and train the immune system to recognize and eliminate pre cancer cells. The IL-15 superagonist N-803 enhances the effects of the vaccines, increasing the potential for cancer prevention in participants.
Patrick Soon-Shiong, Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio, highlighted the importance of the study, saying, “Understanding mechanisms that might prevent or delay [cancer] onset could potentially change the prospects for tens of thousands of people annually.”
Freshpet, Inc. (FRPT) +11.94%
Fourth Quarter and Full Year 2023 Financial Results
Freshpet, Inc. (FRPT) has reported robust financial results for the fourth quarter and full year ending December 31, 2023. The company’s strategic investments have led to improved profitability and significant operating cash flow, marking a turning point as outlined in the Fresh Future plan announced last year.
Billy Cyr, Freshpet’s CEO, commented on the positive results, stating, “Our strong 2023 results demonstrate that Freshpet has reached an inflection point. In 2024, we intend to continue making strong margin improvement and demonstrate continued capital discipline, while sustaining the net sales growth that Freshpet has become known for.”
Freshpet is positioned to drive growth and profitability in the pet food industry, aligning with the belief that the future of pet food is fresh. The company aims to create significant shareholder value while maintaining its leadership position in the market.
In conclusion, the pre-market gainers present a diverse array of success stories, showcasing the resilience and innovation within their respective industries. Freight Technologies, Inc. (FRGT) secures a significant collaboration with Envases Universales, reaffirming its commitment to efficient cross-border logistics. ImmunityBio, Inc. (IBRX) reaches a crucial milestone in its cancer vaccine trial, potentially reshaping cancer prevention for those with hereditary risk. Freshpet, Inc. (FRPT) reports robust financial results, marking a turning point in profitability and operational success. As we eagerly anticipate our upcoming newsletter, these stories underscore the dynamic landscape of market trends and the exciting potential for researchers to capitalize on emerging opportunities. Stay tuned for a deeper dive into these pre-market gainers in our next report!
